By Sue-Ann Wayow
A TENTH Covid-19 vaccine has received emergency use listing (EUL) by the World Health Organization (WHO).
On Tuesday, WHO approved Nuvaxovim, following its assessment and approval by the European Medicines Agency (EMA).
WHO, in a media release, stated that the new vaccine was developed by Novavax Inc and the Coalition for Epidemic Preparedness Innovations (CEPI) and is the originator product for the Covovax vaccine that received WHO emergency use listing on December 17.
Novavax Inc is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases.
WHO stated that both Nuvaxovim and Covovax were made using the same technologies. They require two doses and are stable at two to eight degrees celsius refrigerated temperatures.
